Skip to main content

Table 3 Calculation results of base cases. Standard deviations are shown in parentheses

From: The effect of model selection on cost-effectiveness research: a comparison of kidney function-based microsimulation and disease grade-based microsimulation in chronic kidney disease modeling

  MSM-dg MSM-kf
Immunosuppressant therapy Control Immunosuppressant therapy Control
Life years (years) 76.35 (± 12.44) 73.89 (± 12.14) 78.80 (± 12.62) 75.80 (± 12.82)
Utility (years) 20.34 (± 4.08) 19.43 (± 4.06) 21.12 (± 4.08) 20.00 (± 4.33)
Cost (1000 USD) 199.98 (± 298.13) 286.85 (± 350.27) 122.99 (± 265.59) 213.42 (± 365.60)
V0 (1000 USD) 86.87 90.43
V1 (1000 USD) 132.29 146.25
  1. MSM-dg Disease grade-based microsimulation, MSM-kf Kidney function-based microsimulation, V0 boundary below which the intervention is dominant; V1 boundary below which the intervention is cost-effective. V0 and V1 are defined in the main text